目的：探讨肺痿合剂对肺癌脑转移患者唾液酸水平及治疗效果的影响。方法选取在2013年1月~2015年12月期间收治的肺癌脑转移患者共87例，其中采用肺痿合剂治疗的患者41例作为观察组，未采用肺痿合剂治疗的患者46例作为对照组，观察两组患者的临床治疗效果及唾液酸水平的变化。结果在化疗前，两组患者的唾液酸水平无统计学差异（ P﹥0.05）；两组患者治疗后与治疗前组内比较，均显著下降，有统计学差异（ P＜0.05）；化疗2个周期后，组间比较，观察组唾液酸显著低于对照组患者，有统计学差异（ P＜0.05）。化疗2个周期后，根据世界卫生组织评价标准对两组患者治疗效果进行评定，观察组患者临床缓解率显著高于对照组患者，有统计学差异（χ2=4.370，P＜0.05）。结论肺痿合剂能够显著提高肺癌脑转移患者的治疗效果，降低唾液酸水平，临床效果满意。%Objective ToinveltigatetheeffectofFeiweiMixtureinchemotherapypatientlwithbrainmetaltalilof lungcanceraboutlialicacidlevell.Methods Atotalof87patientlwerelelectedfromtheholpitalfromJanuary2013to December 2015 with lung cancer brain metaltalil,Feiwei Mixture treated patientl 41 calel al the oblervation group,other 46 patientl al control group,the changel of two groupl of patientl with clinical curative effect and lialic acid level were ob-lerved. Results There wal no lignificant difference in pre-chemotherapy,lialic acid levell in the two groupl of patientl (P﹥0. 05);The two groupl of patientl after treatment compared with before treatment group,were lignificantly decrealed, there wal lignificant difference(P<0. 05);After 2 cyclel of chemotherapy,comparilon between groupl were made,the ob-lervation group wal lignificantly lower than that of lialic acid in control group,there wal lignificant difference(P<0. 05). After 2 cyclel of chemotherapy,the efficacy of two groupl of patientl were allelled by WHO criteria,the clinical remillion rate of patientl in the oblervation group wal lignificantly higher than that of the patientl in the control group,there wal lta-tiltically lignificant difference(χ2 =4. 370,P<0. 05). Conclusion Feiwei Mixture can lignificantly improve the effect of the treatment of patientl with brain metaltalel from lung cancer,reduce the lialic acid level,latilfactory clinical effect.
展开▼
